Polycystic ovary syndrome: An overview

Journal of Pharmacy Practice

Volumn 24, Issue 1, 2011, Pages 94-101

  Whitaker, Kristin Nadine ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Clomiphene citrate; Infertility; Metabolic syndrome; Metformin; Polycystic ovary syndrome

Indexed keywords

CLOMIFENE CITRATE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; FOLLITROPIN; GONADORELIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SPIRONOLACTONE;

ANOVULATION; ARTICLE; BODY MASS; DIET RESTRICTION; EXERCISE; FEMALE INFERTILITY; GENETIC MARKER; GENETIC POLYMORPHISM; HORMONAL REGULATION; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; MENSTRUAL CYCLE; OBESITY; OVARY POLYCYSTIC DISEASE; PHARMACIST; WEIGHT REDUCTION;

EID: 79953851343     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010384632     Document Type: Article

References (59)

1. Hirshfeld-Cytron J, Randall BB, Ehrmann DA, et al. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(5):1587-1594.
2. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-2749. (Pubitemid 38766360)
3. Setji TL, Brown AJ. Comprehensive clinical management of polycystic ovary syndrome. Minerva Medica. 2007;98:175-189. (Pubitemid 47573857)
4. Polycystic Ovary Syndrome. Clinical management guidelines for obstetrician-gynecologists. ACOG Practice. Bulletin number 41. 2002;100(6):1389-1402.
5. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2004 Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800. (Pubitemid 28009567)
7. Pandey S, Bhattacharya S. Impact of obesity on gynecology. Women's Health. 2010;6(1):107-117.
8. Chen M-J, Yang W-S, Yang J-H, et al. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension. 2007;49:1442-1447. (Pubitemid 46809392)
9. Mark W, Dokras A. Polycystic ovary syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost. 2009;35(7):613-620.
10. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med. 2009;10(2):83-90.
11. Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocr Metabo. 2003;88(12): 5801-5807. (Pubitemid 38033054)
12. Weiner CL, Primeu M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovary syndrome to healthy controls. Psychosom Med. 2004;66: 356-362. (Pubitemid 38668404)
13. Bernard L, Ferriday D, Guenther N, et al. Quality of life and psychological well being of polycystic ovary syndrome. Hum Reprod. 2007;22(8):2279-2286. (Pubitemid 47241876)
14. Jedel E, Waern M, Gustafson D, et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod. 2010;25(2):450-456.
15. Cheung LP, Ma RCW, Lam PM, et al. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod. 2008;23(6):1431-1438. (Pubitemid 351770573)
16. Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010;25(1):212-220.
17. Mathur R, Ko A, Laura J. Hwang, et al. Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Dig Dis Sci. 2010;55:1085-1089.
18. O'Connor A, Phelan N, Kyawtun T, et al. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocr Metab. 2010;95(3):1378-1385.
19. Burt Solorzano CM, McCartney CR, Blank SK, et al. Hyperandrogenaemia in adolescent girls: origins of abnormal gonadotropinreleasing hormone secretion. BJOG. 2010;117:143-149.
20. De Leo V, Musacchio MC, Palermo V, et al. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. Drugs Today. 2009;45(10):763-775.
21. Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physcian. 2009;79(8):671-676.
22. Moran LJ, Lombard CB, Lim S, et al. Polycystic ovary syndrome and weight management. Women's Health. 2010;6(2):271-283.
23. Moini A, Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. J Assist Reprod Genet. 2009;26:123-127.
24. Ioannidis A, Ikonomi E, Dimou NL, et al. Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a mendelian randomization meta-analysis. Mol Genet Metab. 2010;99:174-183.
25. Rossi B, Sukalich S, Droz J, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocr Metab. 2008;93(12):4780-4786.
26. Chittenden BG, Fullerton G, Maheshwari A, et al. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009;19(3):398-405.
27. Brown AJ, Setji TL, Sanders LL, et al. Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome. Med Sci Sports Exerc. 2009;41(3):497-504.
28. Vigorito C, Giallauria F, Palomba S, et al. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocr Metab. 2007;92: 1379-1384. (Pubitemid 46556413)
29. Salley KE, Wickham EP, Cheang KI, et al. Position statement: glucose intolerance in polycystic ovary syndrome a position statement of the androgen excess society. J Clin Endocr Metab. 2007;92:4546-4556. (Pubitemid 350223423)
30. Moran LJ, Noakes M, Clifton PM, et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocr Metab. 2004;89:3337-3344. (Pubitemid 38951901)
31. Moral LJ, Noakes M, Clifton PM, et al. Short-term meal replacements followed by dietary marcronutrient restriction enhance weight loss in polycystic ovary syndrome. Am J Clin Nut. 2006;84:77-87. (Pubitemid 44699174)
32. Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003;18(9):1928-1932. (Pubitemid 37107570)
33. Moran LJ, Noakes M, Clifton PM, et al. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin EndocrMetab. 2007;92:2944-2951. (Pubitemid 47236354)
34. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Balsco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced bariatric surgery. J Clin Endocr Metab. 2005;90:6364-6369. (Pubitemid 41759284)
35. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocr. 2010;162:193-212.
36. Trolle B, Flyvbjerg A, Kesmodel U, et al. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod. 2007;22(11):2967-2973. (Pubitemid 351696807)
37. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, et al. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and metaanalysis. Hum Reprod Update. 2009;15(1):57-68.
38. Bee KT, Heutling D, Chen J, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and decrease in insulin resistance. Diabetes. 2008;57:1501-1507.
39. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care. 2007;30(3):471-178.
40. Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, doubleblind multicentre study. Hum Reprod. 2006;21(1):80-89. (Pubitemid 41794294)
41. Tan S, Hahn S, Benson S, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocr. 2007;157:669-676. (Pubitemid 350187385)
42. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334: 574-579. (Pubitemid 126537875)
43. Kosasa TS. Making a case for metformin. OB/GYN. 2003;48: 69-80.
44. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocr Metab. 2004;89(6):2756-2762. (Pubitemid 38766362)
45. Harris-Glocker M, Davidson K, Kochman L. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. Fertil Steril. 2010;93(3):1016-1019.
46. Aroda VR, Ciarali TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocr Metab. 2009;94(2):469-476.
47. Glueck CJ, Moreira A, Goldenberg N, et al. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod. 2003;18(8): 1618-1625. (Pubitemid 36958039)
48. Dickey RP, Holtkamp DE. Development, pharmacology, and clinical experience with clomiphene citrate. Hum Reprod Update. 1996;2(6):483-506. (Pubitemid 27153988)
49. Kousta E, WhiteDM, Frank S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997;3(4):359-365. (Pubitemid 27515543)
50. Dickey RP, Taylor SN, Curole DN, et al. Relationship of clomiphene dose and patient weight to successful treatment. Hum Reprod. 1997;12(3):449-453. (Pubitemid 27156434)
51. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551-556.
52. Matsumoto J, Hata T. Re-evaluation of secondary amenorrheic patients one year after initial diagnosis: a prospective study. J Nippon Med Sch. 2004;71(1):63-68. (Pubitemid 38295821)
53. Bagis T, Gokcel A, Zeyneloglu HB, et al. The effects of shortterm medroxyprogesterone acetate and micronized progestereone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocr Metab. 2002;87(10):4536-4540. (Pubitemid 35247037)
54. Guido M, Romualdi D, Guiliani M, et al. Drosperinone for the treatment of hirsute women with polycystic ovary syndrome: a clinical endocrinological, metabolic pilot study. J Clin Endocr Metab. 2004;89(6):2817-2823. (Pubitemid 38766371)
55. Karrer-Voegeli S, Rey F, Reymond MJ, et al. Androgen dependance of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine. 2009;88(1):32-45.
56. Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009; (2):CD000194.
57. Reismann P, Liko I, Igaz P, et al. Pharmacological options for treatment of hyperandrogenic disorders. Mini Rev Med Chem. 2009;9(9):1113-1126.
58. Karakurt F, Sahin I, Guler S, et al. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomized controlled study. Adv Ther. 2008;25(4):321-328.
59. Shapiro J, Lui H. Treatments for unwanted facial hair. Skin Therapy Lett. 2005;10(10):1-4.